YGEN.L Regulatory News (YGEN)

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Notice of Results

Manchester, UK 12 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will issue its half year results for the six months ending 30 September 2019 on Monday, 2 December 2019.

The Company will host a briefing for private investors that week with Lyn Rees, CEO, and Barry Hextall, CFO, providing a presentation on the results and a business update.

If you would like to register for the briefing, please contact Walbrook PR on 020 7933 8780 or email yourgene@walbrookpr.com.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.